KR20210073532A - 흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물 - Google Patents
흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR20210073532A KR20210073532A KR1020217010706A KR20217010706A KR20210073532A KR 20210073532 A KR20210073532 A KR 20210073532A KR 1020217010706 A KR1020217010706 A KR 1020217010706A KR 20217010706 A KR20217010706 A KR 20217010706A KR 20210073532 A KR20210073532 A KR 20210073532A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- rpl554
- particles
- hfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816447.5 | 2018-10-09 | ||
| GB1816447.5A GB2578093B (en) | 2018-10-09 | 2018-10-09 | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| PCT/GB2019/052863 WO2020074894A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210073532A true KR20210073532A (ko) | 2021-06-18 |
Family
ID=64394831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217010706A Ceased KR20210073532A (ko) | 2018-10-09 | 2019-10-09 | 흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210379053A1 (enExample) |
| EP (2) | EP3960157A1 (enExample) |
| JP (2) | JP7578587B2 (enExample) |
| KR (1) | KR20210073532A (enExample) |
| CN (1) | CN112912064B (enExample) |
| AU (1) | AU2019358585B2 (enExample) |
| BR (1) | BR112021006712A2 (enExample) |
| CA (1) | CA3113167A1 (enExample) |
| CY (1) | CY1124943T1 (enExample) |
| DK (1) | DK3820446T3 (enExample) |
| ES (1) | ES2899744T3 (enExample) |
| GB (1) | GB2578093B (enExample) |
| HR (1) | HRP20220053T1 (enExample) |
| HU (1) | HUE057780T2 (enExample) |
| IL (1) | IL282032A (enExample) |
| LT (1) | LT3820446T (enExample) |
| MX (2) | MX2021003599A (enExample) |
| MY (1) | MY207302A (enExample) |
| PH (1) | PH12021550767A1 (enExample) |
| PL (1) | PL3820446T3 (enExample) |
| PT (1) | PT3820446T (enExample) |
| RS (1) | RS62775B1 (enExample) |
| SG (1) | SG11202102567UA (enExample) |
| SI (1) | SI3820446T1 (enExample) |
| SM (1) | SMT202200044T1 (enExample) |
| WO (1) | WO2020074894A1 (enExample) |
| ZA (1) | ZA202102039B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3231444T1 (sl) | 2014-05-12 | 2020-04-30 | Verona Pharma Plc | Novo zdravljenje |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB2594480A (en) * | 2020-04-28 | 2021-11-03 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| JP2025534762A (ja) * | 2022-10-28 | 2025-10-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | イソキノリノン系化合物を含む医薬組成物及びその調製方法 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1165558B1 (en) | 1999-03-31 | 2003-09-24 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| PH12013500261A1 (en) * | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| US10022303B2 (en) * | 2012-02-28 | 2018-07-17 | Iceutica Pty Ltd. | Inhalable pharmaceutical compositions |
| PT2968313T (pt) * | 2013-03-15 | 2018-02-21 | Verona Pharma Plc | Combinação de fármacos |
| SI3231444T1 (sl) * | 2014-05-12 | 2020-04-30 | Verona Pharma Plc | Novo zdravljenje |
| DK3494962T3 (da) * | 2014-09-15 | 2021-06-21 | Verona Pharma Plc | Flydende inhalationsformulering omfattende RPL554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2018
- 2018-10-09 GB GB1816447.5A patent/GB2578093B/en active Active
-
2019
- 2019-10-09 JP JP2021517866A patent/JP7578587B2/ja active Active
- 2019-10-09 MX MX2021003599A patent/MX2021003599A/es unknown
- 2019-10-09 ES ES19790718T patent/ES2899744T3/es active Active
- 2019-10-09 DK DK19790718.1T patent/DK3820446T3/da active
- 2019-10-09 US US17/280,452 patent/US20210379053A1/en not_active Abandoned
- 2019-10-09 EP EP21198029.7A patent/EP3960157A1/en active Pending
- 2019-10-09 KR KR1020217010706A patent/KR20210073532A/ko not_active Ceased
- 2019-10-09 SI SI201930145T patent/SI3820446T1/sl unknown
- 2019-10-09 LT LTEPPCT/GB2019/052863T patent/LT3820446T/lt unknown
- 2019-10-09 HR HRP20220053TT patent/HRP20220053T1/hr unknown
- 2019-10-09 AU AU2019358585A patent/AU2019358585B2/en active Active
- 2019-10-09 WO PCT/GB2019/052863 patent/WO2020074894A1/en not_active Ceased
- 2019-10-09 PT PT197907181T patent/PT3820446T/pt unknown
- 2019-10-09 CN CN201980065895.8A patent/CN112912064B/zh active Active
- 2019-10-09 SG SG11202102567UA patent/SG11202102567UA/en unknown
- 2019-10-09 HU HUE19790718A patent/HUE057780T2/hu unknown
- 2019-10-09 MY MYPI2021001479A patent/MY207302A/en unknown
- 2019-10-09 CA CA3113167A patent/CA3113167A1/en active Pending
- 2019-10-09 SM SM20220044T patent/SMT202200044T1/it unknown
- 2019-10-09 RS RS20211599A patent/RS62775B1/sr unknown
- 2019-10-09 BR BR112021006712-4A patent/BR112021006712A2/pt unknown
- 2019-10-09 EP EP19790718.1A patent/EP3820446B1/en active Active
- 2019-10-09 PL PL19790718T patent/PL3820446T3/pl unknown
-
2021
- 2021-03-25 ZA ZA2021/02039A patent/ZA202102039B/en unknown
- 2021-03-26 MX MX2024001499A patent/MX2024001499A/es unknown
- 2021-04-04 IL IL282032A patent/IL282032A/en unknown
- 2021-04-06 PH PH12021550767A patent/PH12021550767A1/en unknown
-
2022
- 2022-02-02 CY CY20221100086T patent/CY1124943T1/el unknown
-
2024
- 2024-03-26 US US18/616,878 patent/US20250049781A1/en active Pending
- 2024-06-05 JP JP2024091837A patent/JP2024113096A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250049781A1 (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| DK2435024T3 (en) | Compositions for the respiratory delivery of active agents and related methods and systems | |
| JP4570251B2 (ja) | 医薬用エーロゾル製剤 | |
| EP0731688B1 (en) | Aerosol drug formulations for use with non-cfc propellants | |
| US20060257324A1 (en) | Pharmaceutical solution formulations for pressurised metered dose inhalers | |
| US9655969B2 (en) | Inhalable medicament comprising tiotropium | |
| JP2007508283A (ja) | カルボン酸界面活性剤を含むエアロゾル製剤 | |
| HUP0302036A2 (hu) | Glükokortikoidot tartalmazó készítmény bronchopulmonális betegségek kezelésére | |
| WO2017089404A1 (en) | Pharmaceutical composition | |
| RU2813959C2 (ru) | Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции | |
| HK40061834A (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| US20200163955A1 (en) | Sterile compositions of indacaterol suitable for nebulization | |
| HK40042852B (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| HK40042852A (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| US20110020244A1 (en) | Pharmaceutical compositions | |
| WO2004080382A2 (en) | Novel compositions containing fentanyl | |
| HK1169027B (en) | Compositions for respiratory delivery of active agents and associated methods and systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |